On May 28, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, reported a significant expansion of new indications to its AI-enabled Next platform ahead of the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. Next establishes a new category of "real-time clinical intelligence" — a departure from legacy retrospective analyses and generic EHR alerts — designed to facilitate the delivery of precision medicine.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To demonstrate the real-world impact of these expanded capabilities, Tempus will showcase a landmark study at ASCO (Free ASCO Whitepaper) 2026, describing clinically meaningful improvements in rates of biomarker testing for early-stage non-small cell lung cancer (eNSCLC) after the implementation of Tempus Next. The multi-center prospective study evaluated the deployment of the Tempus Next AI-enabled clinical decision support system (AI-CDSS) across 662 eNSCLC patients at six diverse U.S. community health systems.

The Next platform drove significant behavioral change and successfully closed critical care gaps by analyzing unstructured EHR data to identify patients who did not receive guideline-directed biomarker testing. Key findings from the study include:

The implementation of real-time interventions delivered an absolute testing rate lift of +24% for ALK, +18% for EGFR, and +13% for PD-L1 within 90 days of pathologic diagnosis.
The program translated testing directly into optimized therapy management, with 89% of treated patients receiving guideline-concordant therapy.
The expanded platform will surface insights from patients across six new clinical scenarios in breast, colorectal, ovarian, prostate, and urothelial cancers. Furthermore, Next has introduced a suite of advanced intelligence capabilities that enable precision medicine teams to map patient experiences and develop targeted care gap programs that support their institution’s health equity initiatives.

"The true challenge in precision oncology is the data fragmentation that hides critical care gaps across the patient journey," said Ryan Fukushima, CEO of Data and Apps at Tempus. "By expanding Next, we are providing our health systems partners with a 360-degree view to not only identify these gaps but to quantify the truly addressable opportunities for intervention. Our goal is to ensure that clinical innovation reaches every patient, closing the gap between the latest biomarker-driven therapies and community-level care to improve outcomes at scale."

(Press release, Tempus, MAY 28, 2026, View Source [SID1234666169])

On May 28, 2026 BostonGene, developer of the leading AI model for tumor and immune biology, reported that nine abstracts have been accepted at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting (ASCO) (Free ASCO Whitepaper), scheduled to take place May 30 – June 2, 2026, at McCormick Place Convention Center in Chicago, IL. BostonGene will also exhibit at booth #33137.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstracts underscore the broad clinical utility of BostonGene’s AI-powered models and advanced analytical platforms, including the Tumor Portrait test and Kassandra cell deconvolution. Spanning both tissue and peripheral blood analysis, the featured research showcases how integrating deep genomic, transcriptomic, and immunomic profiling can identify novel actionable biomarkers, predict immunotherapy response and toxicity, and map complex resistance mechanisms. Developed in collaboration with leading institutions such as the UT MD Anderson Cancer Center, Weill Cornell Medicine, and the Parker Institute for Cancer Immunotherapy, these studies highlight BostonGene’s pivotal role in accelerating biomarker discovery and optimizing patient stratification for clinical trials.

Details about the abstracts selected for presentation can be found below:

Poster presentations
Poster number: 273
Title: TROP2 as an actionable biomarker for anal cancer
Date & time: May 30 | 9:00 AM – 12:00 PM
Speaker: Mir Lim, MD, UT MD Anderson

BostonGene and MD Anderson Cancer Center collaborated to perform comprehensive genomic profiling of localized and metastatic anal cancers, assessing TACSTD2 (TROP2) expression as a potential therapeutic biomarker. The analysis found high TACSTD2 expression that correlated with TROP2 immunohistochemistry, supporting its potential use in identifying patients who may benefit from anti-TROP2 antibody-drug conjugates. The study underscores the clinical utility of BostonGene’s Tumor Portrait test in biomarker discovery and validation.

Research conducted in collaboration with UT MD Anderson

Poster number: 257
Title: Developing harmonized tumor microenvironment subtypes for patient stratification in clinical trials
Date & time: May 30 | 1:30 PM – 4:30 PM
Speaker: Sofya Kust, PhD, BostonGene

BostonGene developed an AI-driven harmonized tumor microenvironment (HTME) classification system to improve patient stratification for immunotherapy and targeted therapies across solid tumors. By applying machine learning approaches—including agglomerative clustering, K-nearest neighbors classification, and transcriptomic pathway analysis—to RNA-seq data from more than 40,000 cancer samples, the study identified nine reproducible TME subtypes capturing key biological features such as immune activity, fibrosis, vascularization, and hypoxia. The AI-based framework outperformed existing methods by integrating multiple biological dimensions simultaneously and accurately predicting treatment response and progression-free survival across different cancer types and therapies.

Poster number: 323
Title: Multimodal immunoprofiling of peripheral blood using foundation models of the immune system for predicting immunotherapy response and toxicity in the RADIOHEAD pan-cancer cohort
Date & time: May 30 | 1:30 PM – 4:30 PM
Speaker: Evgeny Barykin, PhD, BostonGene

In collaboration with Parker Institute for Cancer Immunotherapy, BostonGene applied AI-based models of the immune system to analyze blood samples from more than 1,000 cancer patients receiving immune checkpoint inhibitor (ICI) therapy in the RADIOHEAD pan-cancer cohort. By combining RNA sequencing, flow cytometry, and machine learning models trained on 45,000 patient profiles, the study identified immune signatures linked to both treatment response and severe immune-related toxicities. The AI-driven embeddings and multimodal immunoprofiling approach successfully stratified patients into responder, non-responder, and high-risk toxicity groups, highlighting the potential of AI-powered peripheral blood profiling to improve immunotherapy patient selection.

Research conducted in collaboration with Parker Institute for Cancer Immunotherapy

Poster number: 360
Title: Effects of a multimodal TCR/BCR repertoire foundation model on blood RNA-seq–based prediction of severe adverse event risk and rheumatoid arthritis
Date & time: May 30 | 1:30 PM – 4:30 PM
Speaker: Alexander Bagaev, PhD, BostonGene

BostonGene utilized its immune model leveraging multimodal TCR/BCR repertoire data to address two critical clinical challenges: predicting severe immune-related adverse events (irAEs) in cancer patients receiving immune checkpoint inhibitors and detecting rheumatoid arthritis from peripheral blood. By integrating adaptive immune receptor repertoire embeddings with gene expression signatures, the model significantly outperformed traditional immune repertoire analysis approaches—such as clonality, diversity, and V(D)J gene usage metrics—in both predictive accuracy and cross-cohort robustness. These advances enabled earlier risk stratification and more precise immunotherapy management than conventional biomarker methods.

Poster number: 533
Title: Immune priming with the EZH2 inhibitor tazemetostat in B-cell lymphomas receiving CART cell therapy
Date & time: June 1 | 9:00 AM – 12:00 PM
Speaker: Samuel Yamshon, MD, Weill Cornell Medicine

BostonGene applied its multimodal molecular profiling platform to characterize the systemic immune remodeling driven by tazemetostat priming in patients with B-cell lymphomas receiving CART therapy. By integrating high-parameter flow cytometry, RNA sequencing, immune cell deconvolution, and functional gene signature analysis, BostonGene’s analysis revealed systemic immune remodeling associated with enhanced antigen presentation, T-cell activation, and reduced immunosuppressive signaling—supporting the use of EZH2 inhibition for improved CART efficacy and durability.

Research conducted in collaboration with Weill Cornell Medicine

Poster number: 268b
Title: IvoLoC: A phase II trial of ivonescimab (IVO) in endocrine-refractory hormone receptor (HR)-positive or triple-negative (TN) metastatic invasive lobular carcinoma (mILC)
Date & time: June 1 | 1:30 PM – 4:30 PM
Speaker: Jason Mouabbi, MD, UT MD Anderson

In a trial in progress with UT MD Anderson Cancer Center, BostonGene will perform multimodal longitudinal blood and tissue analysis for mILC patients receiving the bispecific antibody targeting PD-1 and VEGF, ivonescimab. Moving beyond traditional efficacy metrics, complex correlates linking clinical outcomes with molecular features are ongoing. By integrating real-time ctDNA dynamics with predictive responder scores, BostonGene aims to identify critical markers of response and resistance needed to optimize treatment durability and refine future trial strategies.

Research conducted in collaboration with UT MD Anderson

Online only
Abstract number: e12594
Title: Examining the tumor microbiology and microenvironment of patients with triple negative inflammatory breast cancer receiving Keynote 522

Stage III triple‑negative inflammatory breast cancer patients receiving KN522 therapy were analyzed with BostonGene’s integrative multimodal platform. By combining intrinsic subtype classification with immune deconvolution, BostonGene successfully mapped the molecular landscape of treatment response. Non-responders were marked by angiogenic and endothelial remodeling and potential biomarkers of brain metastasis risk, demonstrating the platform’s unique capability to predict both therapeutic outcomes and disease progression.

Research conducted in collaboration with UT MD Anderson

Abstract number: e13080
Title: Real-world clinical utility of comprehensive genomic and transcriptomic profiling in metastatic breast cancer (mBC)
Description: Clinicians at MD Anderson Cancer Center utilized BostonGene’s Tumor Portrait test to validate the impact of comprehensive genomic profiling in guiding treatment decisions and predicting outcomes in a heterogeneous real-world mBC cohort. The findings demonstrated that BostonGene’s integrated approach uncovered clinically actionable insights and predictive signatures that directly guided treatment selection and improved patient outcomes.

Research conducted in collaboration with UT MD Anderson

Abstract number: e16004
Title: Association of angiogenic, fibrotic, and immunosuppressive tumor microenvironment with immunotherapy outcomes in metabolic disease–associated biliary tract cancers

Researchers at MD Anderson Cancer Center leveraged BostonGene’s transcriptomic classifiers and KassandraTM cell deconvolution to characterize the tumor microenvironment (TME) of metabolic disease-associated biliary tract cancers. The analysis uncovered a distinct TME in metabolic disease-associated cholangiocarcinoma that likely impairs response to immune checkpoint inhibitors, demonstrating the value of BostonGene’s AI-powered solutions for therapeutic response prediction and trial design.

Research conducted in collaboration with UT MD Anderson

For more information, please visit the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting website. The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO (Free ASCO Whitepaper) Annual Meeting Proceedings.

(Press release, BostonGene, MAY 28, 2026, View Source [SID1234666168])

On May 28, 2026 HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, reported that it will be officially listed on the Taiwan Innovation Board on May 29, 2026, with an underwriting price of NT$120 per share.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HanchorBio is focused on developing differentiated immunotherapies targeting large unmet needs in oncology and autoimmune diseases. The Company’s core technology is its proprietary FBDB platform, which integrates multiple immune-modulating mechanisms into a single molecule and supports the development of multi-target, multifunctional biologic therapies.

Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio, said platform technology is an important foundation for building long-term biotechnology value. By supporting the generation of multiple research and development assets over time, platform capabilities may help diversify risks associated with single-asset drug development while strengthening the long-term potential of the Company’s pipeline.

HanchorBio has built a pipeline of clinical and preclinical candidates, including HCB101, HCB301, HCB303, and HCB206. The Company’s lead program, HCB101, is a CD47-targeting anti-cancer drug candidate designed through precision protein engineering to block tumor immune-evasion signals and restore macrophage-mediated tumor phagocytosis. HCB101 is currently being advanced in Phase 2a clinical development in combination with ramucirumab and paclitaxel for gastric cancer, while also being evaluated in additional indications, including head and neck cancer, colorectal cancer, and triple-negative breast cancer.

HCB301, a trifunctional fusion protein designed to address three key tumor immune-escape mechanisms, has entered Phase 1 clinical trials in the United States, mainland China, and Taiwan. HCB303 is a next-generation multi-target immunotherapy candidate currently under clinical development planning, while HCB206, the Company’s dual-mechanism autoimmune disease program, is viewed as an important potential driver of future pipeline value.

Dr. Liu noted that, in biotechnology licensing and partnership discussions, early clinical data supported by proof-of-concept findings are often a key factor in attracting global pharmaceutical partners. Such data may provide initial evidence of safety, clinical activity, and potential differentiation in patients.

HCB101 has shown encouraging early clinical activity in ongoing multinational Phase 1b/2a studies. In a mid-dose cohort evaluating HCB101 in combination with standard therapy for second-line gastric cancer, the regimen demonstrated an objective response rate (ORR) of 80%, with favorable safety and tumor reduction observations. Preliminary data from gastric cancer and first-line triple-negative breast cancer cohorts have also shown encouraging response and disease control signals. If subsequent Phase 2a proof-of-concept data across multiple indications remain supportive, the Company believes HCB101 may further positioned for global partnering discussions.

HanchorBio is pursuing a multi-indication clinical development strategy for HCB101, designed to support flexible business development opportunities, including licensing, co-development, and potential strategic transactions. Following its licensing agreement last year with Henlius for the development and commercialization rights to HCB101 in mainland China and certain territories, valued at up to US$202 million, HanchorBio has continued to advance discussions with multiple global pharmaceutical companies. The Company is currently engaged in ongoing partnering discussions for global and regional rights to HCB101 outside previously licensed territories.

(Press release, Hanchor Bio, MAY 28, 2026, View Source [SID1234666167])

On May 28, 2026 Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) reported that the Phase II clinical study of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), in combination with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC), has been selected for an oral presentation at the 2026 World Conference on Lung Cancer (WCLC), the world’s most influential scientific meeting in the lung cancer field, taking place September 12–15, where Leads Biolabs will present breakthrough efficacy data based on an expanded patient cohort compared to the previously reported 18-patient dataset.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Previously reported early-stage NSCLC data showed that Opamtistomig combined with chemotherapy achieved a compelling objective response rate (ORR). With extended follow-up, deepening tumor responses and durable tumor shrinkage were observed across multiple subgroups, including immunotherapy-pretreated non-squamous NSCLC, first-line non-squamous NSCLC, and first-line squamous NSCLC.

At WCLC 2026, the Company will present updated data demonstrating high response rates and continuously deepening tumor shrinkage of Opamtistomig in an expanded patient population, along with a safety profile consistent with previous findings. These results further validate the safety breakthrough enabled by conditional 4-1BB activation via the X-body platform and highlight Opamtistomig’s differentiated clinical advantages in first-line NSCLC.

Opamtistomig’s potential as an IO 2.0 pan-tumor backbone therapy is being validated in three key dimensions—broad antitumor activity, long-term survival benefit trends, and a safety profile comparable to PD-(L)1 inhibitors: its clinical development spans 13 solid tumor indications, demonstrating first- or best-in-class potential in multiple tumor types, including NSCLC, extrapulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), and biliary tract cancer (BTC); clear survival benefit trends have been observed in multiple indications, with potential to translate into long-term efficacy benefits with continued follow-up; and with over 600 patients enrolled, Opamtistomig demonstrated a favorable safety profile as monotherapy and in combination with chemotherapy, with no dose-limiting toxicities observed and the maximum tolerated dose not reached at doses up to 25.0 mg/kg.

Executive Commentary
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: "The selection for an oral presentation at WCLC represents strong recognition from the international academic community of Opamtistomig’s innovative mechanism and clinical value, and further validates its breakthrough therapeutic potential in first-line NSCLC. As we accumulate data from larger patient cohorts and longer follow-up, we continue to observe significant trends toward deeper and more durable responses across broader patient populations. We look forward to sharing these important findings with global experts at WCLC and continuing to advance Opamtistomig toward becoming a new backbone of cancer immunotherapy worldwide."

About Opamtistomig
Opamtistomig (LBL-024) is emerging as a next-generation pan-cancer backbone therapy with potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Developed using Leads Biolabs’ proprietary X-Body bispecific platform, Opamtistomig is designed to simultaneously block PD-1/L1 immune suppression and conditionally activate 4-1BB, an agonist pathway, resulting in a potent and synergistic anti-tumor immune response. It has a safety profile comparable to PD-1/PD-L1 inhibitors and demonstrates broader-spectrum anti-cancer potential. To date, Opamtistomig has demonstrated first- or best-in-class potential in Phase II or registrational clinical trials across four indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), biliary tract cancer (BTC), and extrapulmonary neuroendocrine carcinoma (EP-NEC).

As the first 4-1BB–targeting bispecific antibody globally to advance to a single-arm pivotal trial as monotherapy, Opamtistomig has been evaluated in 13 solid tumor indications in China, including 1 pivotal registration trial and 8 proof-of-concept studies. These cover EP-NEC, NSCLC, SCLC, BTC, ovarian cancer (OC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC), malignant melanoma, and other areas with high unmet medical needs.

Mechanistically, 4-1BB agonism can reactivate exhausted T cells and promote robust T-cell proliferation, offering significant promise for PD-1/PD-L1–resistant or immunologically "cold" tumors. Recognizing its clinical potential, Opamtistomig received Breakthrough Therapy Designation (BTD) from China’s National Medical Products Administration (NMPA) in October 2024, and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of neuroendocrine carcinoma in November 2024. Additionally, in January 2026, Opamtistomig was granted Fast Track Designation (FTD) by the FDA and ODD by the European Commission for the treatment of EP-NEC, further underscoring its potential to address unmet medical needs in this patient population.

(Press release, Nanjing Leads Biolabs, MAY 28, 2026, View Source [SID1234666166])

On May 28, 2026 PeproMene Bio, Inc. reported that updated clinical data from its ongoing Phase 1 study evaluating PMB-CT01, an investigational B-cell activating factor receptor (BAFF-R)-targeted CAR T-cell therapy, have been selected for an oral presentation at the 2026 Congress of the European Hematology Association (EHA) (Free EHA Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This presentation will highlight results from the completed dose-escalation portion of the study in relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL), including patients whose cancer has progressed following standard CD19-directed CAR T-cell therapy (NCT05370430).

Among the nine patients treated in this phase, PMB-CT01 demonstrated a promising safety profile with no dose-limiting toxicities, no grade >1 cytokine release syndrome (CRS), and no grade >1 immune effector cell-associated neurotoxicity syndrome (ICANS). Seven of nine patients (78%) achieved a complete response (CR). At the last data cutoff, no relapses had occurred and all responses remained ongoing, with the longest response exceeding 3 years. Responding patients also achieved minimal residual disease (MRD)-negative status, indicating deep remissions with no detectable residual cancer cells.

Building on these results, the trial is actively enrolling patients into expansion cohorts for mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma (FL). Importantly, the first patient treated in this expansion phase – a patient with transformed FL (tFL) who had progressed following CD19 CAR T therapy – achieved a CR at their first disease assessment. tFL is an aggressive form of lymphoma with limited established treatment options.

"When cancer progresses following CD19 CAR T therapy, patients face a significant unmet medical need, with very limited treatment options remaining," said Larry W. Kwak, M.D., Ph.D., scientific founder of PeproMene Bio. "These durable CRs clinically validate BAFF-R as a novel target, while the favorable safety profile observed to date may support future use in outpatient community oncology settings and further exploration in refractory autoimmune diseases."

Presentation Details

Abstract Title: Durable responses and favorable safety of BAFF-R CAR T-cells (PMB-CT01) in patients with relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease

Abstract: EHA (Free EHA Whitepaper)-1611 S287

Date/Time: June 14, 11:00 AM – 12:15 AM CEST

Presenter: Larry W. Kwak, M.D., Ph.D.

About PMB-CT01

PMB-CT01 is a first-in-class BAFF-R-targeted autologous CAR T-cell therapy being evaluated in ongoing Phase 1 trials for relapsed/refractory B-NHL and relapsed/refractory B-ALL. BAFF-R is expressed almost exclusively on B cells and is essential for B-cell survival, reducing the likelihood of antigen-loss escape.

(Press release, PeproMene Bio, MAY 28, 2026, View Source [SID1234666165])